A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia
Phase of Trial: Phase II/III
Latest Information Update: 11 Feb 2016
At a glance
- Drugs CX 516 (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Registrational; Therapeutic Use
- 25 Feb 2009 New source identified and integrated (ClinicalTrials.gov record).
- 24 Jul 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History